Nesiritide
- Generic Name
- Nesiritide
- Drug Type
- Biotech
- CAS Number
- 124584-08-3
- Unique Ingredient Identifier
- P7WI8UL647
- Background
Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.
- Indication
适用于急性代偿性心力衰竭、慢性失代偿性心力衰竭、心肌梗死、心脏导管手术等。由于静脉使用起效快，更适用于急性心力衰竭。
- Associated Conditions
- Acute Decompensated Heart Failure (ADHF)
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 7141
- Registration Number
- NCT00475852
BNP Therapy Observation Unit Outcomes STudy (BOOST)
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Emory University
- Target Recruit Count
- 17
- Registration Number
- NCT00453453
- Locations
- 🇺🇸
Grady Memorial Hosptial, Atlanta, Georgia, United States
Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.
Phase 1
Completed
- Conditions
- Left Ventricular Diastolic Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT00405548
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
Phase 1
Completed
- Conditions
- Asymptomatic Systolic DysfunctionHeart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 37
- Registration Number
- NCT00405639
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Phase 1
Completed
- Conditions
- Congestive Heart Failure
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2012-05-17
- Lead Sponsor
- Horng Chen
- Target Recruit Count
- 58
- Registration Number
- NCT00387621
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Horng Chen
- Target Recruit Count
- 4
- Registration Number
- NCT00348556
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
Phase 3
Completed
- Conditions
- Heart Failure, CongestiveHeart Decompensation
- Interventions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT00288730
Nesiritide Use Following Cardiac Surgery in Infants
Phase 1
Terminated
- Conditions
- Cardiopulmonary BypassHeart Defects, Congenital
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT00281671
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
Phase 3
Completed
- Conditions
- Heart Failure, CongestiveHeart Decompensation
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT00271557
Renal Effects of Intrarenal Nesiritide
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 2
- Registration Number
- NCT00270829
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath